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Ovine pulmonary adenocarcinoma (OPA) is a naturally occurring lung cancer of sheep caused by Jaagsiekte sheep retrovirus (JSRV). The
JSRV envelope glycoprotein (Env) functions as a dominant oncoprotein in vitro and in vivo. In order to develop the basis for the use of OPA as a
lung cancer model, we screened a variety of signal transduction inhibitors for their ability to block transformation by the JSRV Env. Most
inhibitors were not effective in blocking JSRV Env-induced transformation. On the contrary, various Hsp90 inhibitors efficiently blocked JSRV
transformation. This phenomenon was at least partly due to Akt degradation, which is activated in JSRV-transformed cells. Hsp90 was found
expressed in tumor cells of sheep with naturally occurring OPA. In addition, Hsp90 inhibitors specifically inhibited proliferation of immortalized
and moreover primary cells derived from OPA tumors. Thus, OPA could be used as a large animal model for comprehensive studies investigating
the effects of Hsp90 inhibitors in lung adenocarcinoma.
© 2007 Elsevier Inc. All rights reserved.Keywords: Jaagsiekte sheep retrovirus; Lung adenocaricnoma; Large animal models; Sheep; Retroviruses; BetaretrovirusesIntroduction
The understanding of the molecular mechanisms governing
pulmonary oncogenesis has increased tremendously throughout
the last decade (Minna et al., 2002). However, lung cancer is
still the most common cause of death of cancer patients
worldwide and its survival rate after 5 years is extremely poor,
highlighting the urgent need for the development of better
therapies and early detection strategies (Parkin et al., 2005). To
this end, appropriate animal models can be of great help in
understanding the molecular basis of lung cancer, designing
candidate therapeutic interventions, new surgical procedures
and testing novel imaging technologies for early diagnosis.
A variety of mouse models are available for lung cancer
(Dutt and Wong, 2006). Transgenic and especially “condition-
al” mouse models, had a dramatic effect in understanding the⁎ Corresponding author. Fax: +44 141 3302271.
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doi:10.1016/j.virol.2007.09.041contribution of oncogenes in the onset and maintenance of
cancer (Varmus et al., 2005). In the pre-clinical settings,
treatment of xenograft mouse models is routinely the first step
used to test new anticancer drugs. However, most anticancer
drugs fail in phase I and II clinical trials (Rothenberg et al.,
2003).
Neoplasms of domestic animals are not extensively used as
cancer models. The large body of knowledge in mouse genetics,
the possibility to manipulate their genome and the availability of
biological reagents make rodents the natural choice as disease
model organisms. Large and domestic animals are more difficult
and generally more expensive to manage compared to mice or
rats. However, the completion of the sequencing of the genome
of several domestic animal species and the development of new
cloning and transgenic techniques open the possibility to
explore other animal species as cancer models (Khanna et al.,
2006).
Ovine pulmonary adenocarcinoma (OPA) is a naturally
occurring lung cancer of sheep (Fan, 2003) caused by a
Table 1
Effect of inhibitors on JSRV-induced cell transformation of 208F cells
Pathway Inhibitor
name
Inhibitor
concentration
(μM)
Inhibition of
transformation a
(%)
Reversion
of
transformed
phenotype
Janus protein
tyrosine
kinase
JAK inhibitor
I
0.001 n.a. b No
0.005 n.a. No
0.01 n.a. No
0.015 n.a. No
0.05 n.a. No
0.15 0 No
VEGFR VEGF
receptor 2
kinase
inhibitor III
1 0 n.a.
20 n.a. Tx c
SRC (family) PP2 5 41 No
10 73.4 No
PP1 0.0015 No
0.015 0 No
Genistein 25 11.9 No
Inhibitor I 0.044 n.a. No
0.088 n.a. No
0.44 n.a. No
0.88 0 No
Inhibitor II 1.2 0 No
12 TX Tx
Emodin 0.018 n.a. No
18.5 0 No
185 n.a. Tx
SU 6656 0.28 n.a. No
1 22 n.a.
2.8 65.9⁎⁎ Yes
Lavendustin C 2 4 No
Damnacanthal 0.017 n.a. No
0.17 0 No
Platelet-derived
growth
factor
receptor
(PDGF)
Inhibitor I 0.2 n.a. No
2 n.a. No
Inhibitor II 1.1 n.a. No
11 57.5 No
Inhibitor III 0.05 n.a. No
0.08 20 No
0.5 n.a. No
0.8 0 No
AG 1296 1 n.a. No
10 n.a. No
AG 2043 1 n.a. No
10 29.2 No
EGFR PD 153035 0.000025 n.a. No
0.00025 0 No
AG 1478 0.003 n.a. No
0.03 0 No
HSP 90 Herbimycin A 0.2 96 n.a
0.4 100 Yes
Geldanamycin 0.0017 0 n.a.
0.0075 74 n.a.
0.0187 90 n.a.
0.0375 97.9 Yes
0.075 Tx Yes
207M. Varela et al. / Virology 371 (2008) 206–215retrovirus known as Jaagsiekte sheep retrovirus (JSRV)
(Palmarini and Fan, 2003; Palmarini et al., 1999). Among
retroviruses, JSRV follows unique mechanisms to induce cell
transformation since its envelope (Env) glycoprotein functions
as a dominant oncoprotein both in vitro (Allen et al., 2002;
Maeda et al., 2001; Palmarini and Fan, 2003; Palmarini et al.,
1999; Rai et al., 2001) and in vivo (Caporale et al., 2006;
Wootton et al., 2005). The molecular mechanisms underlying
JSRV Env-induced transformation have not been fully charac-
terized but several pieces of evidence point to the involvement
of the Ras-MEK-MAPK and PI3K-AKT pathways (De Las
Heras et al., 2006; Maeda et al., 2005; Palmarini et al., 2001).
OPA shares many similarities with some forms of human lung
adenocarcinomas (Mornex et al., 2003; Palmarini and Fan,
2001). In addition, OPA has several features suggesting that it
can be developed into a useful animal model for lung cancer:
(i) sheep and humans have a comparable lung size and tumor to
body mass ratio; (ii) tumors in OPA can grow for a long time in
the presence of a functional immune system; and (iii) the disease
is experimentally reproducible (Palmarini et al., 1999; Sharp
et al., 1983) and the location/extent of the induced lesions can be
modulated by using replication defective viruses delivered to
specific sites with an intrabronchial delivery (Caporale et al.,
2006).
The aim of this study was to identify signalling pathways
involved in JSRV mediated transformation and to establish the
basis for the use of OPA as a model to study the effects of small
molecule inhibitors in cancer development. We provide data
showing that several Hsp90 inhibitors efficiently block trans-
formation of rodent fibroblasts by the JSRV Env and revert the
phenotype of cells already transformed by this oncoprotein. This
phenomenonwas due at least in part to Akt degradation, which is
normally activated in JSRV-mediated transformation (Caporale
et al., 2006; Palmarini et al., 2001). Importantly, Hsp90 was
found expressed in tumor cells of sheep with naturally occurring
OPA and Hsp90 inhibitors reduced proliferation of primary and
immortalized cell lines derived from OPA tumors. Targeting of
the Hsp90 molecular chaperone has great potential for cancer
therapy (Workman, 2004). Thus, OPA could be used as a large
animal model for comprehensive studies investigating the
effects of Hsp90 inhibitors.
Results
Effects of signal transduction inhibitors in JSRV-induced cell
transformation of rodent fibroblasts
Our first goal was to identify inhibitors of signal trans-
duction pathways that efficiently blocked JSRV Env-induced
cell transformation.0.75 Tx Yes
Radicicol 0.27 n.a. Yes
2.7 55.7 Yes
17-DMAG 0.5 88.8 Yes
Notes to Table 1:
Notes to Table 1:
a Inhibition of transformation was calculated by comparing the number of
foci obtained by the JSRV Env in the presence of each inhibitor or in the
presence of DMSO alone (taken as 100%). Values shown are the average of at
least two experiments.
b Not analyzed.
c A toxic effect was evident at these concentrations.
Fig. 1. Src is involved in part in JSRV Env-induced cell transformation. 208F
cells were co-transfected with 1 μg of an expression plasmid for the JSRV Env
and increasing amounts of a plasmid expressing a dominant negative form of Src
(SrcMF). Results show the average of two independent experiments and are
expressed as a percentage of transformation where the number of foci resulting
from transfection of 1 μg of JSRV Env alone is considered 100%. Bars represent
standard deviation.
Fig. 2. Reversion of transformed phenotype of 208F-tr cells. 208-tr cells derive
from a focus of cells transformed by the JSRV Env. These cells were cultured in
the presence of Hsp90 inhibitors (or DMSO as negative control) and their
morphology was monitored for 5 days. Illustrative examples of 208-tr cells
cultured at higher or lower density in the presence of Hsp90 inhibitors are shown.
208 M. Varela et al. / Virology 371 (2008) 206–215We assessed a total of 22 inhibitors, each of them in two
different experimental settings. In the first series of experiments,
we used a cell line transformed by the JSRV Env (208F-tr) and
determined whether the addition of various inhibitors reverted
the phenotype of the transformed cells to the parental cell line.
Each inhibitor was used at least at two different concentrations
ranging from 1 to 10 times its reported IC50. The highest con-
centration of each inhibitor that did not induce cell toxicity was
used in standard transformation assays performed in the 208F
cell line. In these series of experiments, cells were transfected
with an expression plasmid for the JSRV Env and cultured in the
presence or absence of each inhibitor. Foci of transformed cells
were counted 15 days post-transfection. Each experiment was
repeated at least twice. Results obtained are summarized in
Table 1.
Inhibitors against the Janus protein kinase (JAKs), vascular
endothelial growth factor receptor (VEGFR) and epidermal
growth factor receptor (EGFR) did not affect transformation by
the JSRV Env since no or minimal reduction in the number of
foci was observed in cultures treated with inhibitors compared to
the control ones treated with DMSO. Inhibitors against platelet-
derived growth factor receptor (PDGF) reduced the number of
transformed foci induced by the JSRV Env from 30% to 60% as
compared with cells treated with DMSO alone. However, the
PDGF inhibitors used had a noticeable toxic effect in 208F cells
and consequently the reduction in the number of transformed
foci could be due simply to this phenomenon. Neither the PDGF
inhibitors nor the inhibitors mentioned above were able to revert
the phenotype of 208-tr. These data indicate that signalling
through the JAKs, VEGF receptor, PDGF receptor and EGFR do
not play a major role in JSRV-induced cell transformation of
rodent fibroblasts.
Src contributes to JSRV Env-induced cell transformation
As shown in Table 1, seven of nine inhibitors against the Src
family of non-receptor tyrosine kinases neither reverted thephenotype of 208F-tr cells nor reduced the number of trans-
formed foci in standard JSRV Env transformation assays.
However, SU6656 reverted the transformed phenotype of 208F-
tr cells to a flatter and less translucent morphology and slightly
reduced transformation. In addition, when transformation assays
were performed in the presence of PP2, the number of foci of
209M. Varela et al. / Virology 371 (2008) 206–215transformed cells induced by the JSRV Env was drastically
reduced (∼70%).
The differences on the effects seen among the various Src
inhibitors are not surprising since the specificity and potency
towards each Src family member varies (Blake et al., 2000;
Karni et al., 2003). In addition, PP2 was shown previously to
have an effect on JSRV Env-induced cell transformation (Hull
and Fan, 2006). To further understand the role of Src in JSRV
Env mediated transformation, we co-transfected 208F cells
with the expression plasmid for the JSRV Env and increasingamounts of a dominant negative form of Src (SrcMF) (Timpson
et al., 2001). As shown in Fig. 1, we found a dose-dependent
inhibition of JSRV Env-induced transformation by SrcMF. As
a whole, the data described above suggest that Src may be
partially involved in the mechanisms of JSRV Env-induced cell
transformation.
Hsp90 inhibitors block transformation by the JSRV Env
We next examined several Hsp90 inhibitors including her-
bimycin A (HA), geldanamycin (GA), radicicol and 17-DMAG.
All the above inhibitors suppressed transformation in a dose-
dependent manner (Table 1) and reverted the transformed phe-
notype of 208F-tr cells to a flatter and less translucent mor-
phology compared to control 208-tr cells (Fig. 2). Once the
drugs were removed from the culturing media, cells returned to
display their original transformed phenotype demonstrating that
the drugs had no effect on integration and expression of the
JSRV Env plasmid (Fig. 2, bottom panel). These results indicate
that Hsp90 is involved in the initiation and progression of the
transformation process mediated by the JSRV Env as well as in
the maintenance of the transformed phenotype in vitro.
Hsp90 is a molecular chaperone that participates in the
folding, assembly, maturation and stabilization of “client” pro-
teins including a variety of signalling molecules and transcrip-
tion factors that are crucial for oncogenesis such as AKT, HER2,
c-SRC, NFκB, IGFR1, p53 and RAF among others. Conse-
quently, Hsp90 inhibitors are promising therapeutic drugs
(Blagg and Kerr, 2006).
To further understand the mechanisms underlying the effects
of Hsp90 inhibitors in JSRV-transformed cells, we examined
whether the JSRV Env was an Hsp90 client protein. If this was
the case, the block in transformation and the reversion of the
transformed phenotype seen with the various Hsp90 inhibitors
would be due to association of Hsp90 with the JSRV Env
followed by proteasomal degradation. To this end, we assessed
the expression of the JSRV Env by western blotting in total cell
lysates extracted from transformed 208F-tr cells or from 208F-tr
cells that reverted to a flatter morphology in the presence of
Hsp90 inhibitors (Fig. 3A). We could not detect down-
regulation of the JSRV Env in 208F-tr cells when the phenotype
was reverted to a more flat morphology in the presence of GA or
HA. Moreover, we did not find association between the JSRVFig. 3. Influence of Hsp90 inhibitors on JSRV Env and Akt expression. (A) Total
cell extracts were obtained from 208F-tr cells in the presence of DMSO
(negative control) or from 208-tr that had reverted their transformed phenotype
in the presence of geldanamycin (GA) or herbimycin A (HA). In addition, cell
extracts were also obtained from 208F-tr that returned to the transformed
phenotype once GA or HA were removed from the culturing media. Two
hundred micrograms of cell extracts was immunoprecipitated and analyzed by
western blotting as indicated below each panel. Note that the JSRV Env
expressed in 208F-tr is tagged with a FLAG epitope at its C terminus. TM
indicates the transmembrane domain of the JSRV envelope (Env) glycoprotein.
(B) 208F-tr cells were cultured in serum free media with the addition of 17-
DMAG or DMSO as a negative control for 3, 6, 12 and 24 h. At each time point,
cells were lysed and analyzed by western blotting for the presence of Akt and
pAkt. Detection of γ-tubulin was used as loading control.
210 M. Varela et al. / Virology 371 (2008) 206–215Env and Hsp90 by co-immunoprecipitation assays strongly
suggesting that the JSRV Env is not an Hsp90 client protein
(Fig. 3A).
Hsp90 inhibitors induce Akt degradation
Akt is an Hsp90 client protein and the association between
Hsp90 and Akt modulates the kinase activity of the latter (Sato
et al., 2000). Akt activation plays an important role in JSRV
Env-mediated transformation of 208F cells (Chow et al., 2003;
Liu et al., 2003; Palmarini et al., 2001). Thus, we tested whether
changes in the expression (or phosphorylation status) of Akt
could be the cause of the effects of the Hsp90 inhibitors on
JSRV Env-induced transformation, since the Env itself is not an
Hsp90 client protein. To address this point, we cultured 208F-tr
cells in serum free media with the addition of 17-DMAG
(0.5 μM) (or DMSO as control) for a period of 3, 6, 12 and 24 h.
Thereafter, total cell lysates were analyzed by western blotting.
We observed time-dependent Akt degradation and dephosphor-
ylation at serine 473 when cells were cultured with 17-DMAG
while no changes were seen in the expression of the JSRV Env
or γ-tubulin that was used as loading control (Fig. 3B). No
changes in the phosphorylation status or expression of Akt or
the JSRV Env were observed and no changes in the transformed
morphology of these cells were noticeable when cells were
cultured with DMSO as a control. Akt degradation was ob-
served when the same experiment was performed in the pre-
sence of radicicol, while no changes were noticeable in the level
of expression of the JSRV Env or γ-tubulin (not shown). These
data indicate that the reversion of the transformed phenotypeFig. 4. Hsp90 is expressed in OPA tumor cells. Immunohistochemistry in lung section
cells (characterized by the intracytoplasmic brown color) (A) and Hsp90 (B–D). Hsp-9
cells outside the tumor lesions and moreover in the bronchiolar cells in lung sections
also observed. In panel B, the red arrow indicates tumor cells in an early neoplasticseen with the Hsp90 inhibitors could be due at least in part to the
degradation of Akt.
Hsp90 is expressed in OPA tumor cells in vivo
Above, we demonstrated that Hsp90 inhibitors are able to
block transformation of rodent fibroblasts (and revert the
phenotype of cells already transformed) by the JSRV Env with a
mechanism dependent, at least in part, on Akt degradation.
Here, we assessed whether Hsp90 is expressed in OPA tumors,
in order to determine whether the data obtained in rodent
fibroblasts in vitro could eventually be translated into the JSRV/
OPA model in vivo. Lung sections from tumors of 3 sheep with
naturally occurring OPA and 3 with experimentally-induced
disease were analyzed by immunohistochemistry using anti-
bodies towards the JSRV Env (to verify JSRV expression) or
Hsp90. As expected, the JSRV Env was expressed in the lung
tumor cells of animals with OPA (Fig. 4A). Hsp90 was found to
be highly expressed in tumor cells of both small and more
advanced lesions (Figs. 4B, C) although Hsp90 expression was
also detected in normal bronchiolar, alveolar and interstitial
cells of both OPA and healthy sheep (Figs. 4C, D).
Hsp90 inhibitors reduce proliferation of OPA-derived
immortalized and primary cell lines
In order to better assess the effects of Hsp90 inhibitors on
JSRV-induced transformation, we analyzed their effects on the
growth of tumor cells derived from OPA lesions. Firstly, we
used primary tumor cells from naturally occurring OPA casess from naturally occurring OPA cases show expression of the JSRV Env in tumor
0 is found expressed mainly in the tumor cells. Expression of Hsp90 in epithelial
from both OPA (B, C) and healthy sheep (D, indicated by the black arrow) was
lesion. Bars represent 100 μm.
Fig. 5. Hsp90 inhibitors reduce proliferation of OPA-derived cells. (A) 17-DMAG equally affects the growth rate of tumoral and normal type II pneumocytes while
radicicol specifically reduces proliferation of the tumor cells (p=0.04). (B) 17-DMAG and radicicol significantly reduce (p=0.0002) proliferation of JS8 cells which is
an immortalized cell line derived from a lung tumor of a sheep affected by OPA. Bars in both panels represent the standard deviation.
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cultures. Normal type II pneumocytes were found to express
markers such as SP-A, SP-C and presented lamellar bodies by
electron microscopy (Archer et al., 2007). Tumor cells were
confirmed to express JSRV by the detection of reverse tran-
scriptase activity in the culture supernatants and the detection of
the viral major capsid protein by western blotting (Archer et al.,
2007).
Normal and transformed alveolar type II cells were grown in
the presence or absence of increasing amounts of radicicol or
17-DMAG for 48 h and their proliferation was assessed as
described in Materials and methods. We found a significant
reduction (p=0.04) in the growth of tumor cells as compared to
the normal type II pneumocytes in the presence of 0.1 μM of
radicicol while the effects of 17-DMAG were more variable
(Fig. 5A).
Secondly, we analyzed the effects of Hsp90 inhibition in JS8
cells which is an immortalized cell line derived from a lung
tumor of a sheep affected by OPA (Jassim, 1988; Jassim et al.,
1987). Cells were grown for 72 h in the presence of increasing
amounts of radicicol and 17-DMAG. We found statistically
significant inhibition (p=0.0002) in cell proliferation when
cells were grown in the presence of 17-DMAG and radicicol at
all the concentrations tested (Fig. 5B). Thus, at least radicicol
can block proliferation of OPA tumor cells.
Discussion
The aim of this study was to identify signalling pathways
involved in JSRV-induced cell transformation by the use of
drugs that could efficiently block transformation by the JSRV
Env in vitro and to establish the functional basis for the de-velopment of OPA as a large animal model for lung cancer.
JSRV is unique among oncogenic retroviruses because its
envelope glycoprotein functions as a dominant oncoprotein
(Allen et al., 2002; Maeda et al., 2001; Palmarini and Fan,
2003; Palmarini et al., 1999; Rai et al., 2001). Transfection of a
variety of cell lines with expression plasmids for the JSRV Env
readily results in the induction of foci of transformed cells. In
addition, adeno-associated viral vectors expressing the JSRV
Env induce lung cancer in immunosuppressed mice (Wootton
et al., 2005). Furthermore, replication defective JSRV vectors
expressing only the viral Env induce lung cancer in sheep, the
natural host of JSRV infection (Caporale et al., 2006). Thus, the
JSRV/OPA model is an excellent system where the significance
of findings obtained in vitro can be immediately translated
in vivo.
We found that the molecular chaperon Hsp90 is involved in
the mechanisms of cell transformation induced by the JSRV
Env. Indeed, various Hsp90 inhibitors efficiently blocked trans-
formation in vitro by the JSRV Env and reverted the mor-
phology of cells already transformed by it. In addition, we
demonstrated that (i) Hsp90 is expressed in OPA tumor cells
and (ii) proliferation of OPA-derived tumor cells is inhibited by
radicicol. The reduction of the proliferation of OPA tumor cells
after drug treatment was modest but this could be due to a
somewhat reduction in the transformed phenotype of the pri-
mary tumor cells considering that JSRV expression decreases
over time with the passaging of these cells (Archer et al., 2007).
Also the JS8 cell line has been passaged extensively and does
not release JSRV viral particles in the supernatants (data not
shown).
Thus, OPA could be used as an alternative large animal
model for the development of Hsp90 inhibitors and the study of
212 M. Varela et al. / Virology 371 (2008) 206–215the molecular mechanisms underlying their effects in cancer
development. The JSRV Env is not an Hsp90 client protein
considering that (i) Hsp90 and the JSRV Env do not co-
immunoprecipitate and (ii) Hsp90 inhibitors do not affect the
levels of expression of the JSRV Env in 208-tr cells reverted to a
flatter untransformed morphology. Hsp90 inhibitors reduced the
levels of Akt expression in 208F cells transformed by the JSRV
Env. Activation of the PI3K/Akt pathway is one of the features
displayed by cells transformed by the JSRV Env and the
inhibitory effects of the Hsp90 inhibitors in this system could be
due, at least in part, to Akt degradation.
Lung cancer is a multi-step process that involves the accu-
mulation of genetic and epigenetic alterations that cause the
activation of several signal pathways simultaneously (Digel and
Lubbert, 2005; Girard et al., 2000). Ideally, therapeutic inter-
ventions for cancer should be able to interfere with a variety of
signal transduction pathways that are involved in cell trans-
formation. Heat shock proteins have been found to be over-
expressed in several hematological and solid human cancers,
including lung cancer (Chant et al., 1995; Santarosa et al., 1997;
Senju et al., 2006; Yufu et al., 1992). For reasons that yet remain
to be fully clarified, Hsp90 extracted from tumor cells has a
higher binding affinity for 17-AAG than Hsp90 extracted from
normal tissue, allowing the accumulation of the drug in tumors
(Kamal et al., 2003). Moreover, Hsp90 inhibitors have been
shown to reduce proliferation of several human lung cancer cell
lines and induce further growth inhibition when combined with
irradiation (Senju et al., 2006). The ability of Hsp90 inhibitors
to disrupt a variety of signalling pathways that are involved in
the development of cancer makes them ideal therapeutic agents
for the treatment of lung cancer.
The mechanisms of cell transformation by the JSRV Env are
not completely clarified but involve the PI3K-Akt, the Ras-
MEK-MAPK pathways and possibly, as shown in this study,
also Src considering that two Src inhibitors and a dominant
negative Src (SrcMF) reduced JSRV Env transformation. All
these pathways have been implicated in the development of
human lung cancer (Brognard et al., 2001; Kolch, 2002; Vivanco
and Sawyers, 2002; Zhang et al., 2007). Thus, JSRV-mediated
transformation can be a useful model to study the molecular
mechanisms underpinning the effects of Hsp90 inhibitors on
particular cell signalling molecules in tumors where several
pathways are activated simultaneously, both in vitro and in vivo.
There is an increasing need of animal models for studying the
safety and efficacy of the numerous anticancer drugs that are
under development (Collis, 2006). OPA can be experimentally
reproduced with a short incubation period (∼4–12 weeks) when
lambs are inoculated intratracheally with concentrated virus
preparations (Fig. 6). Under these circumstances, the primary
target cells of infection produce new infectious virus that is able
to infect and hence transform new cells leading to the appearance
of lesions of different sizes that tend to coalesce. It could be
argued that the use of this model could be “overpowering” even
for effective drugs, given that new infectious virus expressing a
dominant oncoprotein is continuously produced. However, we
recently developed a JSRV-replication-defective virus (JS-RD)
(Caporale et al., 2006) that proved to be oncogenic in a highpercentage of inoculated lambs. In addition, JS-RD can be
inoculated by bronchoscopy in well-defined anatomical regions
of the lungs, increasing the opportunity to develop intravitam
imaging techniques where lesion development is continuously
monitored.
The finding that the effects of inhibitors of Hsp90 in cell
transformation can be studied in this system demonstrates that
OPA could be used as tool for the development and im-
provement of other Hsp90 inhibitors. Although animals affected
by OPA have not been used to test the therapeutic potential of
any drugs so far, inhibitors of Hsp90 offer an interesting op-
portunity to challenge OPA in this regard considering the
promising in vitro findings shown in this study. In conclusion,
OPA could be used as a model where integrated approaches and
protocols including imaging for early diagnosis, chemotherapy,
radiotherapy and surgery could be experimented and developed.
In this respect, OPA (and in general large animal cancer models)
can be a valid alternative to rodent models.
Materials and methods
Inhibitors
All inhibitors used in this study were purchased from
Calbiochem. The inhibitors and their concentration of use are
listed in Table 1.
Cells and transformation assays
208F cells were grown in Dulbecco's modified Eagle's
medium with high glucose (4.5 g/l) supplemented with 10%
fetal bovine serum (FBS) at 37 °C in a 5% CO2 atmosphere and
95% humidity. Transformation assays were performed by trans-
fecting 5×105 208F cells (per 10 cm diameter plate) with
pCMV3JS21ΔGP (Maeda et al., 2003; Palmarini et al., 1999;
Rai et al., 2001), an expression plasmid of the JSRV Env or an
empty vector using Calphos mammalian transfection kit
(Clontech) following the manufacturer's instructions. Cells
were washed 12–16 h after transfection with phosphate-
buffered saline (PBS) and split into 4×6 cm plates. Cell culture
medium was replaced every other day for 1 week with the
addition of 1 μM of dexamethasone. Thereafter, two cell culture
dishes were treated with inhibitor and the remaining two with
DMSO as negative control. Foci of transformed cells were
counted 14 days post transfection and ranged between zero
and 300 per dish depending on the degree of inhibition of
transformation. Transformation assays with a dominant nega-
tive form of Src (Timpson et al., 2001) were performed by
transfecting 1 μg of pCMV3JS21ΔGP and increasing amounts
of SrcMF (kindly provided by Valerie Brunton). Foci of
transformed cells were counted 14 days post transfection.
To monitor the effects of various signal transduction inhi-
bitors on cells already transformed by the JSRV Env, we used
208F-tr cells. 208F-tr derive from a focus of 208F cells trans-
formed by JSRV Env tagged with a FLAG epitope. 208F-tr
were allowed to reach 60% confluence before inhibitors (or
DMSO) were added to the media for 5 days.
Fig. 6. Extension of the OPA lesions can be modulated by the use of replication competent or incompetent JSRV viruses. Cartoon representing two experimental
models of OPA. (A) Young lambs have many available target cells (pneumocytes type II or possibly pulmonary stem cells) that can be infected and transformed by
JSRV. In turn, the neoplastic cells produce infectious virus that can then infect and transform other target cells resulting in many satellite and coalescing lesions. On the
other hand, experimental inoculation of young lambs with the replication incompetent JS-RD virus (B) will result in infection and transformation of target cells that do
not produce infectious virus, resulting in tumor nodules derived from a single transformed cell. The cartoon is only a schematic representation of the histopathological
lesions in OPA. Tumor cells in OPA grow usually in a well-organized manner along the alveolar walls.
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Ovine primary alveolar type II cells from healthy sheep or
tumor cells from sheep with OPA were isolated, cultured and
characterized as described previously (Archer et al., 2007).
Briefly, primary cells were cultivated in the selective epithelial
medium Quantum 286 (PAA, Pasching, Austria) complemented
with keratinocyte growth factor (KGF 10 ng/ml, Abcys), hepa-tocyte growth factor (HGF 5 ng/ml, Abcys), penicillin/
streptomycin and cultured in 5% CO2 at 37 °C. Tumor cells
derived from OPA tumors presented a proliferative advantage
compared to cells derived from normal lungs as observed
previously (Suau et al., 2006).
Normal and tumor alveolar type II cells were plated in 96
wells plates (5×102 cells/ well) and cultured for 48 h in the
presence of radicicol or 17-DMAG. Thereafter, cell prolifera-
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Viability Assay (Promega, Charbonnières, France). Experi-
ments were repeated independently three times with at least two
replicates per each experiment. Data were analyzed using a two-
way ANOVA test.
JS8 is an immortalized cell line derived from lung tumors of
a sheep with naturally occurring OPA (Jassim, 1988; Jassim
et al., 1987). JS8 cells were plated in 96-well dishes at a density
of 103 cells/well and grown in F12-DMEM media supplemen-
ted with 10% of FBS with or without the addition of radicicol or
17-DMAG for 72 h. Cell proliferation was measured using the
WST-1 assay (Roche) following the instructions of the manu-
facturer and data were analyzed using an unpaired t-test.
Antibodies
Antibodies for AKT and phosphorylated AKT (S473) were
purchased from Cell Signalling. Monoclonal anti-Flag M2 anti-
bodies were purchased from Sigma. Hsp90 antibodies were
purchased from Santa Cruz Biotechnology. Secondary anti-
rabbit IgG peroxidase linked F(ab') fragment from donkey was
purchased from Amersham Biosciences. Peroxidase-conjugated
goat anti-mouse antibodies were purchased from Jackson
Research.
Co-immunoprecipitation assays
Cells were lysed with SDS-NP-40 lysis buffer [0.5% Sodium
Deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 0.5% NP-
40, 50 mM TRIS, 150 mM NaCl, protease inhibitors cocktail
(Complete-Roche) and 1 mM of PMSF] or with a milder lysis
buffer (20 mM HEPES, 150 mM NaCl, 0.5% beta maltoside
and 0.5% of Triton-X) and immunoprecipitated and analyzed by
western blot as previously described (Varela et al., 2006).
Immunohistochemistry
Four- to six-micrometer lung sections from healthy sheep
(n=2), lambs with experimentally induced OPA (n=3) or
sheep with naturally occurring OPA (n=3) were stained with
hematoxylin and eosin and examined by light microscopy for
tumor lesions. Tumors were confirmed to be caused by JSRV by
immunohistochemistry using antibodies towards the JSRV Env
or the JSRV matrix (MA) as previously described (Caporale et
al., 2006; Salvatori et al., 2004). Expression of Hsp90 in OPA
tumor cells was investigated by using anti Hsp90 antibodies
(Santa Cruz.). The EnVision (Dako) visualization system was
used for both the detection of JSRV proteins and Hsp90.
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